Is the drug holiday over for post-menopausal women taking osteoporosis medications? - Australian College of Rural and Remote Medicine

Duration

2 hrs

Profession

Physician

# of Credits

4.0

Accreditation

ACRRM

Expiry Date

2020-12-18

Osteoporosis is often a “silent” disease, remaining undiagnosed until a fracture occurs. Timely diagnosis by GPs and optimal treatment reduces the risk of further fractures by up to 30%, 50% and 70% in patients with non-vertebral, hip and vertebral fractures, respectively. A burden of disease analysis commissioned by Osteoporosis Australia and based on data from the Geelong Osteoporosis Study estimated that in 2012, 4.74 million (66%) of people over the age of 50 in Australia had osteoporosis or osteopenia – low bone density that is often the precursor to osteoporosis. The prevalence of osteoporosis and osteopenia is estimated to rise by 31% (6.2 million) by 2022. This will result in a 30% increase in the annual fracture incidence, from approximately 141,000 fractures in 2012 to approximately 183,000 in 2022. Approximately 70% of minimal trauma fractures occur in women, with incidence increasing with age in both sexes.

This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points. This activity is approved for 4.00 PRPD Points.

Damian Flanagan
MBBS, MWell, DipRACOG
South Coast Medical
Blairgowrie, Victoria, Australia

Terence Diamond
MBBCh, MRCP, FRACP
Associate Professor, Conjoint appointment,
University of New South Wales
Staff Specialist, Senior Endocrinologist,
St George Hospital, Sydney

On completion of this program, participants will be better able to:

  1. Recall the different modes of action, clinical onset and duration of effect of osteoporosis pharmacotherapies
  2. Counsel patients on the safety and efficacy of long-term use of osteoporosis pharmacotherapies
  3. Evaluate the current data regarding discontinuation of osteoporosis therapy
  4. Review how to discontinue osteoporosis pharmacotherapies to reduce the risk of medication related osteonecrosis of the jaw and atypical femoral fractures and to minimise subsequent rebound fracture risk


Related Courses